However, due to the poor outcomes of ABC-type advanced-stage DLBCL and DLBCLs that co-express MYC and BCL2 (without chromosomal translocations) in response to R-CHOP, it is often recommended that these patients enroll in a clinical trial (UpToDate 5, https://www.uptodate.com/contents/initial-treatment-of-advanced-stage-diffuse-large-b-cell-lymphoma). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.